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Abstract Levodopa/Carbidopa, respectively, Levodopa/
Benserazide is the most effective treatment for Parkinson’s
disease and during the progress of the disease, patients will
inevitably need to be treated with it. Nonetheless, after a
certain time period most of the patients experience side
effects. Mainly disturbing are motor and non-motor fluc-
tuations and dyskinesia. Numerous options from changing
the medication regimen, to continuos dopaminergic
drug delivery via apomorphine or Duodopa pumps and
stereotactical interventions are available. The physician’s
responsibility is to choose the right therapeutic procedure
for each timepoint of the patient’s disease. In this review,
we provide an up to date overview of the available
strategies.
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Introduction
As one of the main pillars in the therapy of Parkinson’s
disease (PD), Levodopa/Carbidopa (LC), respectively,
Levodopa/Benserazide (LB) is the mainstay in treatment,
with the highest antiparkinsonian efficacy. LC/LB increa-
ses the survival rate and the quality of life and will have
to be added to any treatment regimen in the longrun
(Olanow et al. 2004). Side effects of LC/LB treatment
comprise nausea, vomiting, orthostatic hypotension, cog-
nitive impairment, psychosis and obsessive compulsive
disorders (OCD). In the ELLDOPA study, Fahn (2005) was
able to show the significant improvement of Parkinson’s
patients, measured on the Unified Parkinson Disease Rat-
ing Scale (UPDRS), depending on the dose of LC/LB
therapy. However, depending on the daily dose of LC/LB,
the onset of motor fluctuations and dyskinesia is often in as
little time as 5–6 months to 2 years (Stocchi and Rabey
2011; Fahn 2005). Due to this disease development and
Levodopa-induced side effects (LID), therapeutic regimens
have to be adjusted and different strategies have to be
considered.
Fluctuations and dyskinesia
The underlying pathophysiology of Levodopa-induced
fluctuations and dyskinesia is unknown, but the overall
opinion is that it might be due to a discontinuous stimulation
of the striatal dopamine receptors as opposed to the contin-
uous supply of dopamine in the healthy individual (Olanow
et al. 2006). Especially younger patients, with a PD onset
before the age of 50, with high intake of LC/LB for an
increased duration of time are at risk for developing motor
fluctuations and dyskinesia (Kostic et al. 1991). In addition,
female sex seems to be a risk factor (Schrag and Quinn 2000).
Motor fluctuations can present as ‘‘end-of-dose’’ or ‘‘wear-
ing-off’’ phenomenon, sometimes with even unpredictable
‘‘off’’ episodes. In addition, a delayed ‘‘on’’ or no ‘‘on’’
response after medication intake may occur. Non-motor
fluctuations can present not only as severe anxiety, rest-
lessness and mood swings but also as physical symptoms like
urinary disorder, hyperhidrosis, fatigue and sleep disorders
(Barone et al. 2009; Antonini et al. 2008a). Dyskinesias may
appear at the highest level of Levodopa effectiveness as
‘‘peak dose’’ dyskinesia, but may also present as biphasic
dyskinesia, before and after LC/LB dose interval.
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Once fluctuations and dyskinesia emerge, the pharma-
codynamic response changes, resulting in a narrowing of
the ‘‘therapeutic window’’ and a specific levodopa thresh-
old is needed for a sufficient clinical response (Mouradian
et al. 1989). Motor fluctuations can primarily be kept under
control by increasing the daily dose of LC/LB, and hence,
increase ‘‘on’’ time, by risking the occurrence of dyskinesia
or applying more frequently smaller dosages of LC/LB,
consequently reduce dyskinesia but venture to increase the
‘‘off’’ time. Shortening the intervals between the LC/LB
intakes may, however, reduce the compliance of patients
(Grosset et al. 2005). Before changing a current medical
schedule, the patient should be reminded of the reduced





Dopamine concentrations can be increased by blockage of
the monoamine oxidase-B (MAO-B) leading to a reduced
metabolism of dopamine in the brain. Selegiline (SE) was
the first MAO-B inhibitor approved by the FDA in 1996.
Daily treatment with 10 mg SE leads to an improvement of
3 points on the total UPDRS and 1.7 points on the motor
subscale of the UPDRS after 3 months (Parkinson Study
Group 1993). Since the metabolites of SE, metamphet-
amine and amphetamine, are capable to inhibit the
peripheral monoamine oxidase-A (MAO-A) and therefore
hold a potential risk of dietary tyramine-provoked hyper-
tensive crisis, high dosages of SE should be avoided.
Adding 0.5–1 mg rasagiline (RA) to the LC/LB therapy
results significantly in a reduced ‘‘off’’ time and an increase
in ‘‘on’’ time as shown in the PRESTO (Parkinson Study
Group 2005) and LARGO study (Stocchi and Rabey 2011;
Rascol et al. 2005). The excellent side effect profile of RA
has been confirmed in the ADAGIO trial, which showed no
significant differences in adverse events between placebo
treated patients and study participants receiving 1–2 mg of
RA (Olanow et al. 2009). Data from preclinical studies
have suggested that MAO-B inhibitors may have neuro-
protective properties (Heikkila et al. 1984). Considering
clinical studies, only the open-label extension of the
TEMPO study demonstrated that early RA treatment pro-
vided a long-term clinical benefit, suggesting at least some
rationale for a disease-modifying effect of RA (Hauser
et al. 2009). However, the MAO-B inhibitors may reinforce




Levodopa is partly metabolised by the catechol-O-methyl
transferase (COMT). Inhibitors of COMT increase the
elimination half-life of Levodopa and boost the effect of
each tablet by approximately 30 %. Two selective inhibi-
tors are commonly used: Entacapone (a peripheral COMT
inhibitor) and Tolcapone (a peripheral and central acting
COMT inhibitor). Tolcapone possesses the ability of
greater COMT inhibition (Deane et al. 2004) but since
sporadic cases of hepatotoxicity have occurred, regular
blood test is mandatory. Besides this distinctive feature,
side effects resemble LC/LB. Adjunction of a COMT
inhibitor to the LC/LB treatment leads to an increase in
‘‘on’’ time, a reduction in ‘‘off’’ time and an improvement
of motor scores in the fluctuating PD patient (Parkinson
Study group 1997). However, the adjunct of Entacapone to
LC/LB failed to delay the time of onset or reduce the
frequency of dyskinesia as shown in the STRIDE-PD study
(Stocchi et al. 2010). In this double blind trial, every 3.5 h
LC/LB or LC/LB plus entacapone (LE) was administered.
Patients who received LE had an increased risk in devel-
oping dyskinesia compared to the control group. Dyski-
nesia under LE treatment were even more common when
patients were younger than 65 years of age, of male sex,
with a body weight [75 kg, with a disease duration less
then 2 years and an additional treatment with a MAO-B
inhibitor or dopamine agonist (Stocchi et al. 2010).
Levodopa and dopamine agonists
The commonly oral used dopamine agonists (DA) are ro-
pinirole, piribedil and pramipexole. Rotigotine is applied
transdermally. DA is often applied as an initial treatment in
PD due to their low potential to develop dyskinesia (Rascol
et al. 2000). However, the majority of patients receiving
DA will also need LC/LB after 2–5 years (Holloway et al.
2004). Being initially developed as an add-on therapy to
LC/LB, several studies have shown a significant reduction
of ‘‘off’’ time of about 1.1–1.5 h per day (Olanow et al.
1994; Pinter et al. 1999). Nowadays, mainly 24 h pro-
longed release formulations of DA are in use and have
shown significant reduction of ‘‘off’’ time (Pahwa et al.
2007). Side effects resemble LC/LB treatment; however,
increased daytime sleepiness and skin irritations in the
transdermally applied form may occur. Recent reports have
also linked DA therapy to pathologic gambling, eating
disorders and hypersexuality (Stocchi 2005; Antonini and
Cilia 2009). Interestingly, the use of ropinirole as initial
therapy of early PD showed a reduced incidence of
dyskinesia for up to 5 years, regardless of supplemental
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LC/LB therapy (Rascol et al. 2000). Recently, Watts et al.
(2010) investigated that the addition of prolonged release
ropinirole to LC/LB therapy delays the occurrence of
dyskinesia. In addition, non-motor fluctuations can
improve from add-on therapy of DA to LC/LB. The
RECOVER study showed that adjunction of 24 h trans-
dermal rotigotine treatment is associated with significant
benefits in the management of early morning motor
impairment, nocturnal sleep disturbances and non-motor
daytime symptoms such as fatigue and mood changes
(Trenkwalder et al. 2011).
Therapeutic algorithm regarding non-invasive
therapeutical options
Figure 1 offers an overview how treatment should be
adjusted according to the occurrence of common subtypes
of dyskinesia and motor fluctuations.
Invasive therapeutical options
If symptoms cannot sufficiently be controlled by orally
applicated medication, invasive therapeutical options must
be considered. Continuous dopaminergic drug delivery
(CDD) can be achieved by continuous subcutaneous
apomorphine infusions (CAI) or duodenal infusions of
Levodopa (Duodopa) via portable minipumps (Hilker et al.
2011). Constant dopaminergic stimulation of the receptors
is associated with a reduced risk of motor fluctuations
compared to treatment with intermittent dosages of stan-
dard oral LC/LB (Obeso et al. 1994). In healthy individu-
als, dopaminergic neurons in the substantia nigra fire at a
constant frequency (Grace and Bunney 1984) and striatal
dopamine levels are not subject to temporary fluctuations
(Venton et al. 2003).
Apomorphine
Apomorphine is a D1/D2 receptor DA with a short half-life
of nearly 45 min and is, therefore, extremely effective
considering time from injection to onset of clinical effects
and mean duration of symptom relief (Neef and van Laar
1999). Apomorphine injections via pen administration are
reasonable for a rapid relieve of a sudden ‘‘off’’ fluctuation
during the daytime and nighttime and to conquer end-of-
dose biphasic dyskinesia (Frankel et al. 1990). Continuous
infusion can be enabled by an apomorphine pump. Via this
modified insulin pump, a programmed infusion rate is dis-
pensed in most cases using a 12–16 h regimen. If needed,
the pump can administer apomorphine for 24 h and does not
have to be discontinued overnight. This has resulted in a
reduced nocturnal off-time (Reuter et al. 1999). Further-
more, a specifically defined bolus application can be given
whenever needed. Treatment should be started under
medical supervision and a premedication with domperidone
should be utilised to reduce side effects (Bowron 2004). For
analysis of circulating antibodies against erythrocytes, a
Fig. 1 Therapeutic algorithm
for orally applicated medication
according to symptoms
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Coombs test should be performed beforehand. One of the
main side effects are skin reactions, located at the injection
side resulting in a formation of small nodules (Deleu et al.
2004). Other side effects include increased daytime sleep-
iness, nausea, dizziness, renal impairment and orthostatic
hypotension (Manson et al. 2001; Stocchi et al. 2001).
Neuropsychiatric changes like hallucinations and psychosis
are rare but can be observed with high dosages of apo-
morphine. CAI may provide a significant improvement of
mood (Morgante et al. 2004).
Duodopa
Duodopa is a combination of Levodopa (20 mg/ml) and
Carbidopa (5 mg/ml) applied in form of a gel into the
duodenum. Preceding the permanent therapy, a test appli-
cation period of Duodopa via a nasoduodenal catheter
system is generally used. If this is well tolerated by the
patient and symptoms improve, a percutaneous, endoscopic
gastrostomy (PEG) is performed and Duodopa is delivered
via a portable pump and a duodenal catheter. If the reten-
tion period is 24 h, Duodopa is given as a monotherapy. If
the Duodopa treatment is subject to a 16 h regimen, a
prolonged release Levodopa tablet is often administered
before bedtime. A number of studies have shown a sig-
nificant reduction of time in ‘‘off’’ and a significant
increase of time in ‘‘on’’, as well as a reduction of dyski-
nesia (Antonini et al. 2008b; Eggert et al. 2008). In addi-
tion, an improvement of the non-motor symptoms
including sleep and pain, gastrointestinal, urological and
cognitive issues was stated (Honig et al. 2009). Adverse
events are mainly due to technical reasons like dislocation,
obstruction and breakage of the duodenal catheter. In very
rare cases, PEG related side effects are monitored. These
include peritonitis and local stoma inflammation.
Deep brain stimulation
The use of continuous high frequency ‘‘deep brain’’ stim-
ulation (DBS) was established in the early 90s and is
widely used with great benefit (Benabid et al. 1994). The
implanted electrodes can be adjusted by changing the
voltage, the pulse width and the frequency to improve
symptoms and/or reduce potential side effects. In PD
patients, the stimulation of either the subthalamic nuclei
(STN) or the internal global pallidum (GPi) is mainly
performed. The duration of benefit following GPi DBS is,
however, variable. After STN DBS, an improvement in all
main cardinal features of PD as well as a reduction of the
mean severity and duration of dyskinesia has been docu-
mented in several studies (Limousin et al. 1998; Krack
et al. 2003; Weaver et al. 2012). The best predictor for a
favourable result is a good Levodopa response (Charles
et al. 2002). Ideal candidates for STN DBS are patients
below the age of 70 years, with motor fluctuations and
dyskinesia or tremor and without cognitive or behavioural
deficits. Side effects of the DBS include intracranial
haemorrhage and infarction. Postoperational complications
Fig. 2 Invasive therapeutical
options for advanced
Parkinson’s disease treatment
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involve confusion, pneumonia, infection and in older
patients pulmonary embolism (Voges et al. 2007). Lead
breakage, extension wire failure, impulse generator mal-
functions—generally referred to as hardware-related com-
plications—typically appear within the first 3 months after
operation (Baizabal Carvallo et al. 2012; Lyons et al.
2004). Stimulation-induced side effects include dysarthria,
hypophonia, dizziness, eyelid opening apraxia and oculo-
motor deficits (Deuschl et al. 2006). Neuropsychiatric
changes like post surgery depression and especially a
13-fold increased risk for suicide within the first year after
STN DBS have been the cause for concern (Voon et al.
2008). A recent study did not find a difference in functional
health measured by time spent in ‘‘on’’ and ‘‘off’’, behav-
ioural side effects, cognition and mood in patients who
received GPi DBS or STN DBS (Odekerken et al. 2013).
Conclusion regarding invasive therapeutical options
The indication for any invasive therapeutical option—
continuous infusion of apomorphine or Duodopa via pumps
or DBS via stereotactical operation—should be carefully
placed (compare Fig. 2). As apomorphine pumps are small
and of lower weight compared to Duodopa pumps, it need
less technical requirements and are generally easy to apply
and completely reversible. CAI is often used as an interim
solution before DBS. The side effects can be generally
controlled well; however, a continuation of the orally
administered medication is almost always necessary. Until
today comparative studies with CAI and Duodopa have not
been accomplished. However, the effect of Duodopa on
‘‘off’’ time is distinct. DBS shows great benefit in control-
ling PD symptomatology and offers more independence for
patients than treatment with pumps; however, the indication
for undergoing stereotactical operation must be strictly
adhered to receive a satisfying outcome. For a good clinical
outcome with any invasive therapeutical option, a high
patient motivation is needed, a necessary detailed patient
education, regular follow-up visits in a specialised setting
and a stable support of the patient by his environment.
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